The performance of companies tied to the drug's past presents a challenging investment picture . While the initial surge generated substantial returns , generic competition have significantly eroded revenue. Investing in associated pharmaceutical firms now requires a thorough assessment of intellectual property safeguards, evolving patient shifts ,